Back to today’s briefing

Story perspectives

AbbVie Bets $350M on Promising Obesity Drug GUB014295

3/3/2025

28 4

Summary

Story summary

AbbVie is making waves in the obesity treatment arena by securing Gubra's promising drug GUB014295 for a hefty $350 million upfront, with the deal potentially soaring to $2.23 billion. This strategic move positions AbbVie to rival popular GLP-1 medications like Wegovy. Early Phase 1 trials reveal a hopeful 3% weight loss in participants, hinting at a brighter future for this innovative treatment.

1 of 1

Story summary

AbbVie is making waves in the obesity treatment arena by securing Gubra's promising drug GUB014295 for a hefty $350 million upfront, with the deal potentially soaring to $2.23 billion. This strategic move positions AbbVie to rival popular GLP-1 medications like Wegovy. Early Phase 1 trials reveal a hopeful 3% weight loss in participants, hinting at a brighter future for this innovative treatment.